After splitting into two companies in January, Abbott Laboratories has pulled the plug on lobbying work that two law firms did for it in Washington, lobbyists disclosed Monday.
Foley Hoag and Williams & Jensen stopped advocating for Abbott on December 31, the day before AbbVie Inc. spun off from the North Chicago, Ill.- based pharmaceutical giant, according to lobbying termination reports filed with Congress. AbbVie sells Abbott's brand-name pharmaceuticals, leaving generic drugs to the new Abbott.
Abbott, which spent $500,000 on federal lobbying during the first quarter of this year, currently has its own staffers and lobbyists from seven firms registered with Congress to advocate for it, congressional records show. Brownstein Hyatt Farber Schreck and Olsson Frank Weeda Terman Matz are among the firms.
Foley Hoag started lobbying for Abbott in 2007, according to congressional records. Most recently in 2012, Kim and Foley Hoag senior policy adviser J. Kevin Brennan lobbied on several matters, including implementation of the health care reform law and drug safety legislation. Abbott last year paid Foley Hoag $120,000 for its advocacy.
Williams & Jensen lobbied for Abbott for most of the past 13 years, except from June 2002 to August 2004. The firm in 2012 deployed Lynch and nine of her colleagues to advocate for Abbott on tax reform and financial services matters, as well as health care issues. Williams & Jensen last year received $200,000 from Abbott for its efforts.